# GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

> **NCT04673149** · PHASE1,PHASE2 · COMPLETED · sponsor: **GeneOne Life Science, Inc.** · enrollment: 171 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** GLS-5310
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04673149
- **Lead sponsor:** GeneOne Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-31
- **Primary completion:** 2021-03-03
- **Final completion:** 2023-05-10
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673149, "GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04673149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*